Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $46.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by Citigroup from $38.00 to $46.00 in a report released on Thursday,Benzinga reports. Citigroup currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the company. The Goldman Sachs Group lowered their price target on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a report on Thursday, November 20th. Truist Financial raised their price objective on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Royal Bank Of Canada lowered Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $57.00 to $28.00 in a research report on Wednesday, November 19th. Bank of America increased their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Finally, Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of “Hold” and an average price target of $40.67.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $27.47 on Thursday. The company has a market capitalization of $1.61 billion, a P/E ratio of -3.86 and a beta of 0.89. The company’s 50-day simple moving average is $28.05 and its two-hundred day simple moving average is $33.24. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider James William Burns sold 2,932 shares of the company’s stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the sale, the insider owned 31,718 shares in the company, valued at $859,240.62. This represents a 8.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brian Goff sold 18,703 shares of the stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $506,664.27. Following the sale, the chief executive officer directly owned 136,583 shares in the company, valued at $3,700,033.47. This trade represents a 12.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,303 shares of company stock valued at $901,977 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in AGIO. T. Rowe Price Investment Management Inc. purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at about $25,000. Assetmark Inc. raised its holdings in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals during the first quarter valued at about $40,000. First Horizon Corp bought a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $45,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $49,000.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Zacks Research raised several near‑term and medium‑term EPS estimates for AGIO, trimming projected losses across multiple quarters (examples: Q1‑2026 to ($1.83) from ($1.85); Q2‑2026 to ($1.90) from ($1.95); Q3‑2026 to ($1.88) from ($1.93); Q4‑2026 to ($1.83) from ($1.87)). These revisions point to modestly better operating/forecasted results versus prior expectations. Article Title
• Positive Sentiment: Zacks also lowered the magnitude of expected full‑year losses: FY2026 was revised to ($7.44) from ($7.60) and FY2027 to ($6.37) from ($6.69), signaling an expected path toward smaller annual losses. Article Title
• Positive Sentiment: Zacks published an FY2028 EPS projection of ($3.61), a notable improvement vs. prior-year loss levels and an indication analysts expect a meaningful narrowing of losses over the next two years. Article Title
• Neutral Sentiment: Short‑interest reporting flagged 0 shares short as of Mar 6, with a days‑to‑cover of 0.0; the data appears anomalous/erroneous and provides no actionable signal about current short pressure.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.